1. The Need for an Iterative Process for Assessing Economic Outcomes Associated with SSRIs

   • Tracy L. Skaer
   • David A. Sclar
   • Richard S. Galin

   Current Opinion 27 October 2012 Pages: 205 - 214

2. The Epidemic of Alzheimer’s Disease

   • Neil Johnson
   • Tim Davis
   • Nick Bosanquet

   Review Article 27 October 2012 Pages: 215 - 223

   

3. Costs of Deep Foot Infections in Patients with Diabetes Mellitus

   • Gunnel Ragnarson Tennvall
   • Jan Apelqvist
   • Magnus Eneroth

   Original Research Article 27 October 2012 Pages: 225 - 238

   

4. Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation

   • Josephine A. Mauskopf
   • Anke Richter
   • Grant Maclaine

   Original Research Article 27 October 2012 Pages: 239 - 251

   

5. Cost Implications for the Use of Inhaled Anti-Inflammatory Medications in the Treatment of Asthma

   • Ronald J. Ozminkowski
   • Shaohung Wang
   • David Schutt

   Original Research Article 27 October 2012 Pages: 253 - 264

   

6. Cost Effectiveness of Abciximab During Routine Medical Practice

   • Shelby Ogilvie Reed
   • C. Daniel Mullins
   • Laurence S. Magder

   Original Research Article 27 October 2012 Pages: 265 - 274

   

7. The Economic Value of a New Insulin Preparation, Humalog® Mix 25™

   • George Dranitsaris
   • Christopher J. Longo
   • Loren D. Grossman

   Original Research Article 27 October 2012 Pages: 275 - 287

   

8. Glipizide

   • Rachel H. Foster
   • Greg L. Plosker

   Adis Pharmacoeconomic Drug Evaluation 27 October 2012 Pages: 289 - 306